Volume 47, Issue 1 , Pages 41-52, January 2008
Suicide Ideation, Plan, and Attempt in the Mexican Adolescent Mental Health Survey
ABSTRACT
Objective
No representative data among adolescents in Mexico exist on the prevalence and risk factors for suicide ideation, plan, and attempt despite a recent increase in suicide deaths.
Method
Data are presented from the Mexican Adolescent Mental Health Survey, a representative household survey of 3,005 adolescents ages 12 to 17 in metropolitan Mexico City who were gathered in 2005, regarding lifetime prevalence and age-of-onset distributions of suicide ideation, plan, and attempt and demographic and psychiatric disorders risk factors.
Results
Lifetime ideation was reported by 11.5% of respondents, whereas 3.9% reported a lifetime plan and 3.1% a lifetime suicide attempt. Onset of suicidality started around age 10 and at age 15 showed the highest hazards. Suicide ideators were more likely to report a plan and attempt within the first year of onset of ideation. Suicidality was more likely to occur among females. The presence of one or more mental disorders was strongly related to suicide ideation, plan, and attempt. Among ideators only dysthymia was consistently related to a plan and attempt.
Conclusions
Intervention efforts should focus on assessment and target adolescents with mental disorders, particularly mood disorders, to be effective in prevention.
Key Words: epidemiology , mental disorders , prevalence , risk factors , suicide , attempt
To access this article, please choose from the options below
This work was made possible by support from American Foundation for Suicide Prevention-Standard Research Grant (to G.B.). The Mexican Adolescent Mental Health Survey was supported by CONACYT and SEP (grant no. CONACYT-SEP-SSEDF-2003-CO1–22 ) and by the National Institute of Psychiatry Ramon de la Fuente Muñiz (DIES- 4845). This survey was carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. These activities were supported by the National Institute of Mental Health (R01MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R01-TW006481), the Pan American Health Organization, Eli Lilly & Co., Ortho-McNeil Pharmaceutical, GlaxoSmith Kline, and Bristol-Myers Squibb.
Disclosure: The authors report no conflicts of interest.
PII: S0890-8567(09)62083-9
doi:10.1097/chi.0b013e31815896ad
© 2008 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 47, Issue 1 , Pages 41-52, January 2008
